Anke Van der Perren

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8581492/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Host oligodendrogliopathy and α-synuclein strains dictate disease severity in multiple system atrophy. Brain, 2023, 146, 237-251.	3.7	10
2	Rab7 reduces α-synuclein toxicity in rats and primary neurons. Experimental Neurology, 2022, 347, 113900.	2.0	10
3	LRRK2 Ablation Attenuates Alpha-Synuclein–Induced Neuroinflammation Without Affecting Neurodegeneration or Neuropathology In Vivo. Neurotherapeutics, 2021, 18, 949-961.	2.1	10
4	The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathologica, 2020, 139, 977-1000.	3.9	149
5	Increased P2X7 Receptor Binding Is Associated With Neuroinflammation in Acute but Not Chronic Rodent Models for Parkinson's Disease. Frontiers in Neuroscience, 2019, 13, 799.	1.4	35
6	Chronic nigral neuromodulation aggravates behavioral deficits and synaptic changes in an α-synuclein based rat model for Parkinson's disease. Acta Neuropathologica Communications, 2019, 7, 160.	2.4	9
7	Identifying a glucose metabolic brain pattern in an adeno-associated viral vector based rat model for Parkinson's disease using 18F-FDG PET imaging. Scientific Reports, 2019, 9, 12368.	1.6	5
8	Peripheral Inflammation Regulates CNS Immune Surveillance Through the Recruitment of Inflammatory Monocytes Upon Systemic α-Synuclein Administration. Frontiers in Immunology, 2019, 10, 80.	2.2	45
9	Temporal changes in neuroinflammation and brain glucose metabolism in a rat model of viral vector-induced I±-synucleinopathy. Experimental Neurology, 2019, 320, 112964.	2.0	12
10	Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Scientific Reports, 2018, 8, 6580.	1.6	54
11	Altered mGluR5 binding potential and glutamine concentration in the 6-OHDA rat model of acute Parkinson's disease and levodopa-induced dyskinesia. Neurobiology of Aging, 2018, 61, 82-92.	1.5	29
12	Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	327
13	Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector. Journal of Visualized Experiments, 2016, , 53670.	0.2	8
14	Noninvasive Imaging Reveals Stable Transgene Expression in Mouse Airways After Delivery of a Nonintegrating Recombinant Adeno-Associated Viral Vector. Human Gene Therapy, 2016, 27, 60-71.	1.4	10
15	Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration. Molecular Neurodegeneration, 2015, 10, 23.	4.4	11
16	Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein. Frontiers in Behavioral Neuroscience, 2015, 9, 68.	1.0	41
17	Binocular pattern deprivation interferes with the expression of proteins involved in primary visual cortex maturation in the cat. Molecular Brain, 2015, 8, 48.	1.3	6
18	FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease. Neurobiology of Aging, 2015, 36, 1559-1568.	1.5	68

#	Article	IF	CITATIONS
19	Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiology of Aging, 2015, 36, 1543-1558.	1.5	75
20	Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice. Neurobiology of Aging, 2014, 35, 2625-2636.	1.5	44